OncoHelix is the first laboratory in
Canada to adopt MSK-ACCESS®
powered with SOPHiA DDM™
BOSTON and ROLLE,
Switzerland, July 24,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a
cloud-native healthcare technology company and a leader in
data-driven medicine, announced today that OncoHelix, an
internationally recognized research and diagnostics laboratory for
precision diagnostics, will implement MSK-ACCESS® powered with
SOPHiA DDM™. The organization, which currently uses the SOPHiA
DDM™ Platform for myeloid testing, will use the new liquid
biopsy solution to advance its oncology testing capabilities.
OncoHelix will be live on MSK-ACCESS® powered with SOPHiA
DDM™ later this summer.
OncoHelix is based in Calgary,
Canada, and offers specialized genomic and molecular testing
services globally. OncoHelix works in partnership with the
Hematology Translational Lab (HTL) at the University of Calgary and has helped significantly
advance the University's precision oncology and immunology research
pipelines.
"Our mission at OncoHelix is to offer exceptional clinical-grade
molecular and immune profile testing. That mission is predicated on
using the most cutting-edge technology to allow for the rapid
validation of genomic panels, sequencing, and analysis," said
Dr. Pinaki Bose, co-founder
and Executive Vice President, OncoHelix. "The SOPHiA
DDM™ Platform has supported our mission over the last year,
and we look forward to implementing MSK-ACCESS® powered with SOPHiA
DDM™ to advance our liquid biopsy offering."
Liquid biopsy testing provides an alternative testing method to
traditional solid tumor biopsy, which can be especially helpful
when patients are facing limitations such as insufficient material
or poor tissue quality, or simply need a less invasive method of
biopsy. Liquid biopsy testing extracts cell-free DNA (cfDNA) from
blood plasma, revealing circulating tumor DNA (ctDNA). This
approach, obtained through a simple blood draw, expedites clinical
decisions, accelerates results for researchers and clinicians, and
streamlines monitoring.
"OncoHelix has quickly become a trusted leader in precision
oncology testing and that is due, in part, to its unrelenting focus
on offering the most advanced technology solutions on the market,"
said John Carey, Managing Director,
NORAM, SOPHiA GENETICS. "We are excited to expand our relationship
with OncoHelix by offering this new liquid biopsy solution, and
continue supporting the company's commitment to tackling cancer
research head-on via targeted testing."
MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized version
of a highly validated ctDNA assay developed by Memorial Sloan
Kettering Cancer Center (MSK) that involves the deep sequencing of
146 key cancer-associated genes. The offering combines the
sophisticated analytics, state-of-the-art algorithms, and global
network of the SOPHiA DDM™ Platform, with the scientific and
clinical expertise of MSK in cancer genomics to provide a
best-in-class liquid biopsy solution.
For more information, visit SOPHiAGENETICS.com, or connect
on LinkedIn. For more information on OncoHelix,
visit oncohelix.org, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a cloud-native healthcare technology company on a mission to
expand access to data-driven medicine by using AI to unlock
insights to deliver world-class care to patients across the globe.
It is the creator of SOPHiA DDM™, a platform that analyzes complex
genomic and multimodal data and generates real-time, actionable
insights for a broad global network of hospital, laboratory, and
biopharma institutions. For more information,
visit SOPHiAGENETICS.COM and connect with us
on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
Memorial Sloan Kettering (MSK)
has institutional financial interests related to SOPHiA
GENETICS.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management.
Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-expanded-relationship-with-canada-based-oncohelix-302205564.html
SOURCE SOPHiA GENETICS